The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: Implication in stepwise leukemogenesis and response to Gleevec
Open accessAbstract
To explore the genetic abnormalities that cooperate with AML1-ETO ( AE ) fusion gene to cause acute myeloid leukemia (AML) with t(8;21), we screened a number of candidate genes and identified 11 types of mutations in C-KIT gene ( mC-KIT ), including 6 previously undescribed ones among 26 of 54 (48.1%) cases with t(8;21). To address a possible chronological order between AE and mC-KIT, we showed that, among patients with AE and mC-KIT , most leukemic cells at disease presentation harbored both genetic alteration, whereas in three such cases investigated during complete remission, only AE , but not mC-KIT , could be detected by allele-specific PCR. Therefore, mC-KIT should be a subsequent event on the basis of t(8;21). Furthermore, induced expression of AE in U937-A/E cells significantly up-regulated mRNA and protein levels of C-KIT. This may lead to an alternative way of C-KIT activation and may explain the significantly higher C-KIT expression in 81.3% of patients with t(8;21) than in patients with other leukemias. These data strongly suggest that t(8;21) AML follows a stepwise model in leukemogenesis, i.e., AE represents the first, fundamental genetic hit to initiate the disease, whereas activation of the C-KIT pathway may be a second but also crucial hit for the development of a full-blown leukemia. Additionally, Gleevec suppressed the C-KIT activity and induced proliferation inhibition and apoptosis in cells bearing C-KIT N822K mutation or overexpression, but not in cells with D816 mC-KIT . Gleevec also exerted a synergic effect in apoptosis induction with cytarabine, thus providing a potential therapeutic for t(8;21) leukemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Blume-Jensen, P., & Hunter, T. (2001) · Nature · doi:10.1038/35077225 · Cited by 3,738
Buchdunger, E., Cioffi, C. L., Law, N., Stover, D., Ohno-Jones, S., Druker, B. J., & Lydon, N. B. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38879-2 · Cited by 1,274
Oncogenic Transcription Factors in the Human Acute Leukemias
Look, A. T. (1997) · Science · doi:10.1126/science.278.5340.1059 · Cited by 1,187
G ENETICS OF M YELOID L EUKEMIAS
Kelly, L. M., & Gilliland, D. G. (2002) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.3.032802.115046 · Cited by 523
AML1–ETO downregulates the granulocytic differentiation factor C/EBPα in t(8;21) myeloid leukemia
Pabst, T., Mueller, B. U., Harakawa, N., Schoch, C., Haferlach, T., Behre, G., Hiddemann, W., Zhang, D.-E., & Tenen, D. G. (2001) · Nature Medicine · doi:10.1038/86515 · Cited by 463
Higuchi, M., O'Brien, D., Kumaravelu, P., Lenny, N., Yeoh, E.-J., & Downing, J. R. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00016-8 · Cited by 440
Yuan, Y., Zhou, L., Miyamoto, T., Iwasaki, H., Harakawa, N., Hetherington, C. J., Burel, S. A., Lagasse, E., Weissman, I. L., Akashi, K., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.171321298 · Cited by 431
Amann, J. M., Nip, J., Strom, D. K., Lutterbach, B., Harada, H., Lenny, N., Downing, J. R., Meyers, S., & Hiebert, S. W. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.19.6470-6483.2001 · Cited by 339
Care, R. S., Valk, P. J. M., Goodeve, A. C., Abu‐Duhier, F. M., Geertsma‐Kleinekoort, W. M. C., Wilson, G. A., Gari, M. A., Peake, I. R., Löwenberg, B., & Reilly, J. T. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04362.x · Cited by 323
The 8;21 translocation in leukemogenesis
Peterson, L. F., & Zhang, D.-E. (2004) · Oncogene · doi:10.1038/sj.onc.1207727 · Cited by 302
Cited by
Paschka, P., Marcucci, G., Ruppert, A. S., Mrózek, K., Chen, H., Kittles, R. A., Vukosavljevic, T., Perrotti, D., Vardiman, J. W., Carroll, A. J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.9500 · Cited by 663
Miettinen, M., & Lasota, J. (2005) · Applied Immunohistochemistry & Molecular Morphology · doi:10.1097/01.pai.0000173054.83414.22 · Cited by 556
Schittenhelm, M. M., Shiraga, S., Schroeder, A., Corbin, A. S., Griffith, D., Lee, F. Y., Bokemeyer, C., Deininger, M. W. N., Druker, B. J., & Heinrich, M. C. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2050 · Cited by 468
Strumberg, D., Clark, J. W., Awada, A., Moore, M. J., Richly, H., Hendlisz, A., Hirte, H. W., Eder, J. P., Lenz, H.-J., & Schwartz, B. (2007) · The Oncologist · doi:10.1634/theoncologist.12-4-426 · Cited by 419
Acute myeloid leukemia stem cells and CD33-targeted immunotherapy
Walter, R. B., Appelbaum, F. R., Estey, E. H., & Bernstein, I. D. (2012) · Blood · doi:10.1182/blood-2011-11-325050 · Cited by 321
Metadata
- Authors
- Wang, Y.-Y., Zhou, G.-B., Yin, T., Chen, B., Shi, J.-Y., Liang, W.-X., Jin, X.-L., You, J.-H., Yang, G., Shen, Z.-X., Chen, J., Xiong, S.-M., Chen, G.-Q., Xu, F., Liu, Y.-W., Chen, Z., & Chen, S.-J.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2005-01-13
- Volume
- 102
- Issue
- 4
- Pages
- 1104-1109
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2095023562
- Cited by
- 276
- References
- 44
- FWCI
- 18.03
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: Implication in stepwise leukemogenesis and response to Gleevec. https://app.cochat.ai/papers/10.1073/pnas.0408831102
- The paper
- Wang, Y.-Y., Zhou, G.-B., Yin, T., Chen, B., Shi, J.-Y., Liang, W.-X., Jin, X.-L., You, J.-H., Yang, G., Shen, Z.-X., Chen, J., Xiong, S.-M., Chen, G.-Q., Xu, F., Liu, Y.-W., Chen, Z., & Chen, S.-J. (2005). AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: Implication in stepwise leukemogenesis and response to Gleevec. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.0408831102
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.